Terumo, a Japanese medical device manufacturer, announced that it has incurred a total loss of $610 million, including impairment losses, following the termination of a supply agreement with its U.S.-based customer, CSL Plasma [1]. CSL Plasma, which operates blood plasma donation centers, decided to switch to devices from other suppliers for some of its locations, prompting the end of the partnership [1].
As a direct result of this development, Terumo has trimmed its full-year forecast, reflecting the significant financial impact of losing this major customer [1]. The company did not provide further details on the revised forecast or specify the extent of the impairment losses beyond the total figure [1].
No additional market reactions, analyst opinions, or forward-looking statements were provided in the article [1].
CONCLUSION
Terumo's loss of its supply agreement with CSL Plasma has resulted in a substantial $610 million hit and a downward revision of its full-year forecast. The event marks a significant setback for the company, with immediate financial consequences and potential implications for its future outlook.